Novogene Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 26, 2022 at 04:09 am EDT
Share
Novogene Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 386.63 million compared to CNY 365.31 million a year ago. Net income was CNY 18.87 million compared to CNY 32.91 million a year ago. Basic earnings per share from continuing operations was CNY 0.05 compared to CNY 0.09 a year ago. Diluted earnings per share from continuing operations was CNY 0.05 compared to CNY 0.09 a year ago.
Novogene Co Ltd is a China-based company principally engaged in gene sequencing. The Company mainly relies on high-throughput sequencing technology and bioinformatics analysis technology to establish gene sequencing platforms. Combined with multi-omics research technology, the Company provides multi-level scientific and research technical services and solutions for life science basic research, medical and clinical application research. Based on the technology accumulation in gene sequencing and its application fields, the Company independently develops genetic testing medical equipment. The Company's services mainly include life science basic scientific research services, medical research and technical services, and database-building sequencing platform services. Its other services and products include gene mutation detection kits, coronavirus disease nucleic acid test service and DA8600 sequencers. The Company conducts its businesses in domestic and overseas markets.